Apellis Pharmaceuticals (NASDAQ:APLS) Insider Nur Nicholson Sells 2,618 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 2,618 shares of Apellis Pharmaceuticals stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total transaction of $58,093.42. Following the sale, the insider directly owned 81,046 shares of the company’s stock, valued at $1,798,410.74. This represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Apellis Pharmaceuticals Price Performance

APLS traded up $0.20 during trading on Thursday, reaching $20.53. The stock had a trading volume of 2,191,474 shares, compared to its average volume of 3,495,767. The business has a 50-day moving average of $22.86 and a 200-day moving average of $23.41. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $31.17. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The stock has a market cap of $2.60 billion, a PE ratio of 66.23 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. The firm had revenue of $458.58 million during the quarter, compared to analysts’ expectations of $364.58 million. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The company’s revenue for the quarter was up 133.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.46) EPS. As a group, equities research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Parallel Advisors LLC increased its stake in shares of Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after buying an additional 855 shares during the period. Jones Financial Companies Lllp lifted its stake in Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after acquiring an additional 1,373 shares during the period. Osaic Holdings Inc. boosted its holdings in Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares in the last quarter. Allworth Financial LP increased its position in Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after purchasing an additional 857 shares during the period. Finally, Quantbot Technologies LP bought a new position in Apellis Pharmaceuticals in the 3rd quarter worth $64,000. 96.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 29th. Cantor Fitzgerald reduced their price objective on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Tuesday. Mizuho decreased their price objective on Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. Wells Fargo & Company assumed coverage on Apellis Pharmaceuticals in a report on Wednesday, October 15th. They set an “overweight” rating and a $32.00 target price for the company. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and issued a $19.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday. Eleven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $33.65.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.